Labcorp (NYSE:LH) Price Target Raised to $396.00

by · The Markets Daily

Labcorp (NYSE:LH – Free Report) had its price target lifted by Robert W. Baird from $361.00 to $396.00 in a research note issued to investors on Thursday, MarketBeat.com reports. The firm currently has an outperform rating on the medical research company’s stock.

Several other research firms have also weighed in on LH. Leerink Partners set a $410.00 target price on Labcorp in a report on Wednesday. JPMorgan Chase & Co. lifted their price target on Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Bank of America lifted their price target on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. UBS Group boosted their price objective on shares of Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Finally, Mizuho set a $355.00 price objective on shares of Labcorp in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $365.67.

Get Our Latest Stock Analysis on LH

Labcorp Stock Performance

LH opened at $361.96 on Thursday. The stock has a market cap of $29.35 billion, a P/E ratio of 29.69, a P/E/G ratio of 2.05 and a beta of 0.87. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.41 and a quick ratio of 1.53. The stock’s 50 day simple moving average is $323.23 and its 200 day simple moving average is $287.61. Labcorp has a 1-year low of $244.52 and a 1-year high of $371.00.

Labcorp (NYSE:LH – Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share for the quarter, beating the consensus estimate of $4.64 by $0.14. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. Labcorp’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the business posted $4.18 EPS. As a group, equities analysts anticipate that Labcorp will post 18.48 EPS for the current fiscal year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Tuesday, November 24th. Labcorp’s payout ratio is currently 23.63%.

Insider Activity at Labcorp

In other Labcorp news, Director Kerrii Anderson sold 3,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the sale, the director owned 6,563 shares in the company, valued at approximately $2,087,165.26. This represents a 31.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam Schechter sold 4,669 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the transaction, the chief executive officer directly owned 102,565 shares of the company’s stock, valued at $32,858,749.05. The trade was a 4.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 8,593 shares of company stock valued at $2,733,295. 0.84% of the stock is owned by corporate insiders.

Institutional Trading of Labcorp

Several institutional investors and hedge funds have recently made changes to their positions in LH. Signaturefd LLC increased its position in Labcorp by 4.9% during the 3rd quarter. Signaturefd LLC now owns 687 shares of the medical research company’s stock worth $212,000 after purchasing an additional 32 shares in the last quarter. CoreCap Advisors LLC raised its stake in Labcorp by 13.8% in the 3rd quarter. CoreCap Advisors LLC now owns 289 shares of the medical research company’s stock valued at $89,000 after purchasing an additional 35 shares during the last quarter. Krilogy Financial LLC lifted its holdings in Labcorp by 2.4% in the 3rd quarter. Krilogy Financial LLC now owns 1,590 shares of the medical research company’s stock valued at $502,000 after purchasing an additional 37 shares in the last quarter. V Square Quantitative Management LLC lifted its holdings in Labcorp by 1.7% in the 1st quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock valued at $645,000 after purchasing an additional 40 shares in the last quarter. Finally, Meeder Advisory Services Inc. boosted its stake in shares of Labcorp by 4.5% during the 1st quarter. Meeder Advisory Services Inc. now owns 1,021 shares of the medical research company’s stock worth $272,000 after purchasing an additional 44 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Labcorp

Here are the key news stories impacting Labcorp this week:

  • Positive Sentiment: Labcorp reported third-quarter adjusted earnings of $4.78 per share, above the $4.64 consensus estimate, while revenue increased 6.9% year over year to $3.81 billion, topping expectations. The company also raised its outlook, supporting the investment case. Labcorp Q3 2026 Earnings Call Highlights
  • Positive Sentiment: Truist raised its price target to $395 from $365 and maintained a Buy rating, while Robert W. Baird increased its target to $396 from $361 and retained an Outperform rating. The revisions indicate analysts see additional upside after the earnings beat. Truist Raises Labcorp Price Target
  • Positive Sentiment: Zacks identified LH as a highly ranked value stock, potentially attracting investors seeking a combination of earnings strength and reasonable valuation characteristics. Labcorp Is a Top-Ranked Value Stock
  • Neutral Sentiment: Labcorp’s estimated fair value moved modestly higher following third-quarter analyst revisions, suggesting improving expectations but limited near-term valuation support. Labcorp Fair Value Edges Higher
  • Negative Sentiment: Analysts continue to flag potential pressure from changes to Medicare laboratory reimbursement rules under PAMA. That risk may temper the benefit of better earnings and guidance. Labcorp Stock Shrugs Off Q3 Earnings as PAMA Risk Looms
  • Negative Sentiment: A Seeking Alpha contributor downgraded the stock, arguing that investor optimism and the sharp advance toward a 52-week high may have outpaced Labcorp’s underlying upside. Deutsche Bank raised its target to $355 but maintained a Hold rating, reinforcing valuation concerns. Labcorp Rating Downgrade

Labcorp Company Profile

(Get Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.

Further Reading